Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MGTXthis companyMeiraGTx Holdings plc	$9.34	-5.6×	-110.38×	7.86×	-7.4×	-554.4%	94.0%	-130.2%	-140.3%	1971.4%	-70.9%	-7.8%	-15.31×	-0.25×	-8.69×	0.75×	0.0%	6	4.07	3	B
FDMT4D Molecular Therapeutics, Inc.	$12.43	-3.1×	0.86×	5.1×	-2.99×	-184.8%	91.1%	-187.2%	-164.4%	-27.7%	-30.2%	-25.1%	0.04×	0.29×	0×	9.39×	0.0%	3	1.71	2	C
KRYSKrystal Biotech, Inc.	$299.42	34.82×	5.85×	18.34×	33.92×	78.8%	92.6%	41.5%	52.6%	16.8%	13.1%	2.6%	0.01×	-2.48×	0×	9.95×	0.0%	4	40.92	4	A-
LCTXLineage Cell Therapeutics, Inc.	$1.05	-5.96×	8.63×	26.4×	-5.09×	-251.4%	94.2%	-149.6%	-436.5%	-142.6%	-19.7%	-5.1%	0.05×	0.56×	0×	5.2×	0.0%	3	-3.44	1	C-
NTLAIntellia Therapeutics, Inc.	$11.84	-2.36×	1.45×	14.4×	-2.3×	-249.6%	76.5%	-651.7%	-609.9%	-61.5%	-57.7%	-36.4%	0.14×	0.16×	0×	5.08×	0.0%	4	2.17	2	C
OCGNOcugen, Inc.	$0.94	-5.87×	-33.31×	91.83×	-6.97×	-126.5%	45.9%	-1425.7%	-1537.4%	557.7%	-278.6%	-14.1%	-2.72×	-0.24×	-12.13×	1.06×	0.0%	2	-6.2	2	C
Peer median	—	-3.1×	1.45×	18.34×	-2.99×	-184.8%	91.1%	-187.2%	-436.5%	-27.7%	-30.2%	-14.1%	0.04×	0.16×	0×	5.2×	0.0%	3	1.71	2	—